FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value, Measurement Inputs

A summary of the significant inputs is as follows:

Business Acquisition	Benchmark	Comparable Company Revenue Volatility	Discount rate	Maximum Contingent Consideration Payment
Certain assets of the clinical and anatomic pathology laboratory business of Shiel Holdings, LLC	Volume	6.9%	4.5%	$	15
ReproSource, Inc.	Revenue	8.5%	6.5%	$	10

The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis:

			Basis of Fair Value Measurements
			Quoted Prices in Active Markets for Identical Assets/Liabilities		Significant Other Observable Inputs		Significant Unobservable Inputs
March 31, 2020	Total		Level 1		Level 2		Level 3
Assets:
Trading securities	$	52	$	52	$	—	$	—
Cash surrender value of life insurance policies	36		—		36		—
Available-for-sale debt securities	12		—		—		12
Fixed-to-variable interest rate swaps	41		—		41		—
Total	$	141	$	52	$	77	$	12
Liabilities:
Deferred compensation liabilities	$	95	$	—	$	95	$	—
Contingent consideration	6		—		—		6
Total	$	101	$	—	$	95	$	6
Redeemable noncontrolling interest	$	76	$	—	$	—	$	76

			Basis of Fair Value Measurements
December 31, 2019	Total		Level 1		Level 2		Level 3
Assets:
Trading securities	$	59	$	59	$	—	$	—
Cash surrender value of life insurance policies	43		—		43		—
Available-for-sale debt securities	12		—		—		12
Total	$	114	$	59	$	43	$	12
Liabilities:
Deferred compensation liabilities	$	110	$	—	$	110	$	—
Fixed-to-variable interest rate swaps	28		—		28		—
Contingent consideration	7		—		—		7
Total	$	145	$	—	$	138	$	7
Redeemable noncontrolling interest	$	76	$	—	$	—	$	76

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following table provides a reconciliation of the beginning and ending balances of liabilities using significant unobservable inputs (Level 3 of the fair value hierarchy):

	Contingent Consideration
Balance, December 31, 2019	$	7
Total gains/losses included in earnings - realized/unrealized	(1		)
Balance, March 31, 2020	$	6